The Wall Street Journal reported on a new study showing that the price of the 50 top-selling drugs rose an average of 7.8 percent last year. The article discusses efforts to contain drug costs for Medicare beneficiaries by having Medicare negotiate prices directly with the industry.
While it presents the argument of an analyst saying that Medicare could negotiate sharply lower drug prices, it also presents the assertion of a Bush administration official that Medicare would be unable to negotiate lower prices than the private insurers operating within the Medicare program. It would have been helpful to point out that the Veterans Administration gets prices that average 40 percent less than the prices paid by by the insurers operating within Medicare. There is no obvious reason that Medicare, which represents a much larger share of the market than the VA, would not be able to negotiate prices comparable to the prices negotiated by the VA. In fact, Medicare could even arrange to have the VA negotiate prices on its behalf.
Unlike many news organizations, the Prospect has remained staunchly committed to keeping our journalism free and accessible to all. We believe that independent journalism is crucial for a functioning democracy—but quality reporting comes at a cost. From Trump’s threat to the free press to Musk’s influence on our democracy, there is too much at stake in 2025 to stop now.
We’re behind on our goal to raise $75,000 to continue delivering the hard-hitting investigative journalism you’ve come to expect from us. Your support helps us maintain our independence and dig deeper into the stories that matter most.
We need you to make a year-end contribution today. Any amount helps secure our future and ensure we can continue holding power to account.
